| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spermatozoa | 19 | 2025 | 214 | 3.200 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 15 | 2020 | 167 | 3.160 |
Why?
|
| Hospital Mortality | 13 | 2021 | 210 | 2.740 |
Why?
|
| Y Chromosome | 12 | 2025 | 55 | 2.210 |
Why?
|
| Spermatogenesis | 13 | 2025 | 161 | 2.060 |
Why?
|
| Sperm Injections, Intracytoplasmic | 17 | 2015 | 67 | 2.060 |
Why?
|
| Asthma | 11 | 2020 | 416 | 1.940 |
Why?
|
| Genes, Y-Linked | 6 | 2022 | 18 | 1.640 |
Why?
|
| Lung | 17 | 2024 | 492 | 1.590 |
Why?
|
| Pneumonia | 6 | 2021 | 61 | 1.460 |
Why?
|
| Bronchi | 7 | 2018 | 45 | 1.440 |
Why?
|
| DNA-Binding Proteins | 5 | 2025 | 561 | 1.370 |
Why?
|
| Transcription Factors | 7 | 2025 | 735 | 1.360 |
Why?
|
| Japan | 19 | 2021 | 348 | 1.310 |
Why?
|
| Fibroblasts | 10 | 2019 | 281 | 1.250 |
Why?
|
| Lung Neoplasms | 7 | 2020 | 495 | 1.200 |
Why?
|
| Oocytes | 11 | 2022 | 149 | 1.110 |
Why?
|
| Interleukin-8 | 6 | 2016 | 74 | 1.100 |
Why?
|
| DNA Damage | 7 | 2012 | 356 | 1.090 |
Why?
|
| DNA Replication | 8 | 2013 | 148 | 1.090 |
Why?
|
| Sex-Determining Region Y Protein | 3 | 2016 | 12 | 1.010 |
Why?
|
| Male | 74 | 2025 | 23409 | 1.000 |
Why?
|
| Infertility | 2 | 2022 | 21 | 0.990 |
Why?
|
| Bronchodilator Agents | 5 | 2019 | 26 | 0.950 |
Why?
|
| Retrospective Studies | 21 | 2021 | 2544 | 0.900 |
Why?
|
| Eukaryotic Initiation Factor-2 | 2 | 2016 | 18 | 0.890 |
Why?
|
| Mice | 40 | 2025 | 6644 | 0.880 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 2853 | 0.850 |
Why?
|
| Female | 59 | 2025 | 24698 | 0.770 |
Why?
|
| Interleukin-17 | 2 | 2015 | 53 | 0.760 |
Why?
|
| Community-Acquired Infections | 3 | 2021 | 22 | 0.760 |
Why?
|
| Interleukin-13 | 3 | 2018 | 20 | 0.730 |
Why?
|
| Aged | 31 | 2021 | 8214 | 0.730 |
Why?
|
| Cisplatin | 3 | 2018 | 98 | 0.710 |
Why?
|
| Embryonic Development | 9 | 2020 | 83 | 0.700 |
Why?
|
| Animals | 47 | 2025 | 16992 | 0.690 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 187 | 0.680 |
Why?
|
| Humans | 72 | 2025 | 43102 | 0.670 |
Why?
|
| Length of Stay | 3 | 2018 | 229 | 0.650 |
Why?
|
| Patient Discharge | 2 | 2018 | 128 | 0.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 220 | 0.640 |
Why?
|
| Epithelial Cells | 5 | 2015 | 434 | 0.630 |
Why?
|
| Dementia | 2 | 2018 | 160 | 0.610 |
Why?
|
| Bronchoscopy | 2 | 2018 | 7 | 0.610 |
Why?
|
| Semen Preservation | 3 | 2011 | 20 | 0.600 |
Why?
|
| Infertility, Male | 6 | 2019 | 47 | 0.600 |
Why?
|
| Comorbidity | 9 | 2018 | 737 | 0.600 |
Why?
|
| Reproductive Techniques, Assisted | 3 | 2016 | 34 | 0.600 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2018 | 8 | 0.580 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2018 | 91 | 0.570 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 64 | 0.570 |
Why?
|
| Fluorouracil | 1 | 2018 | 47 | 0.560 |
Why?
|
| Inpatients | 1 | 2018 | 78 | 0.550 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2014 | 3 | 0.550 |
Why?
|
| Parkinsonian Disorders | 1 | 2018 | 42 | 0.550 |
Why?
|
| Hospitals | 1 | 2018 | 117 | 0.540 |
Why?
|
| Deglutition Disorders | 1 | 2018 | 25 | 0.540 |
Why?
|
| Body Mass Index | 5 | 2016 | 925 | 0.540 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 83 | 0.530 |
Why?
|
| Exhalation | 2 | 2019 | 10 | 0.530 |
Why?
|
| Thinness | 2 | 2014 | 32 | 0.520 |
Why?
|
| Logistic Models | 7 | 2017 | 1009 | 0.520 |
Why?
|
| Mice, Transgenic | 7 | 2019 | 665 | 0.510 |
Why?
|
| Middle Aged | 26 | 2021 | 12222 | 0.510 |
Why?
|
| Cryopreservation | 3 | 2011 | 39 | 0.500 |
Why?
|
| Airway Resistance | 2 | 2017 | 6 | 0.500 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 133 | 0.500 |
Why?
|
| Hip Fractures | 1 | 2016 | 29 | 0.490 |
Why?
|
| Mice, Inbred C57BL | 17 | 2025 | 1869 | 0.490 |
Why?
|
| Respiratory Mucosa | 3 | 2014 | 41 | 0.490 |
Why?
|
| SOX9 Transcription Factor | 1 | 2016 | 10 | 0.480 |
Why?
|
| X Chromosome | 1 | 2016 | 30 | 0.480 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2014 | 384 | 0.480 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 638 | 0.480 |
Why?
|
| DNA | 4 | 2007 | 592 | 0.480 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 8 | 0.480 |
Why?
|
| Poly I-C | 1 | 2015 | 7 | 0.470 |
Why?
|
| Pneumonia, Aspiration | 1 | 2015 | 1 | 0.470 |
Why?
|
| Models, Econometric | 1 | 2015 | 4 | 0.470 |
Why?
|
| Efficiency, Organizational | 1 | 2015 | 15 | 0.460 |
Why?
|
| Ambulatory Care | 1 | 2016 | 81 | 0.460 |
Why?
|
| Epididymis | 5 | 2020 | 29 | 0.460 |
Why?
|
| Odds Ratio | 5 | 2020 | 587 | 0.460 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 291 | 0.460 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2014 | 5 | 0.450 |
Why?
|
| Cells, Cultured | 13 | 2019 | 1621 | 0.450 |
Why?
|
| Long-Term Care | 1 | 2015 | 55 | 0.440 |
Why?
|
| Octoxynol | 3 | 2011 | 19 | 0.430 |
Why?
|
| Risk Factors | 10 | 2018 | 3994 | 0.430 |
Why?
|
| Databases, Factual | 6 | 2018 | 341 | 0.420 |
Why?
|
| Chromosome Breakage | 3 | 2010 | 14 | 0.420 |
Why?
|
| Zygote | 5 | 2013 | 39 | 0.420 |
Why?
|
| Fertilization in Vitro | 4 | 2010 | 57 | 0.400 |
Why?
|
| Treatment Outcome | 8 | 2019 | 1604 | 0.390 |
Why?
|
| Testis | 7 | 2025 | 207 | 0.380 |
Why?
|
| Inflammation | 5 | 2014 | 758 | 0.380 |
Why?
|
| Cell Nucleus | 4 | 2013 | 383 | 0.380 |
Why?
|
| DNA Repair | 2 | 2011 | 198 | 0.380 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 236 | 0.380 |
Why?
|
| Adult | 21 | 2018 | 13872 | 0.380 |
Why?
|
| Spermatids | 5 | 2015 | 42 | 0.370 |
Why?
|
| Clarithromycin | 2 | 2009 | 9 | 0.370 |
Why?
|
| Obesity | 2 | 2025 | 1151 | 0.370 |
Why?
|
| Inhalation | 1 | 2012 | 8 | 0.370 |
Why?
|
| Oscillometry | 1 | 2012 | 9 | 0.370 |
Why?
|
| Semen | 2 | 2022 | 57 | 0.370 |
Why?
|
| Dithiothreitol | 1 | 2011 | 18 | 0.350 |
Why?
|
| Chromosomes, Mammalian | 2 | 2010 | 18 | 0.350 |
Why?
|
| Pulmonary Fibrosis | 2 | 2024 | 38 | 0.340 |
Why?
|
| Sex Chromosome Aberrations | 2 | 2019 | 8 | 0.340 |
Why?
|
| Pulmonary Alveoli | 3 | 2012 | 28 | 0.330 |
Why?
|
| Ejaculation | 2 | 2007 | 11 | 0.330 |
Why?
|
| Cell Shape | 2 | 2010 | 42 | 0.330 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 44 | 0.320 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 2 | 0.320 |
Why?
|
| Pregnancy | 10 | 2025 | 1772 | 0.320 |
Why?
|
| Cell Dedifferentiation | 1 | 2010 | 4 | 0.320 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 61 | 0.320 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2018 | 53 | 0.310 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2021 | 13 | 0.310 |
Why?
|
| Live Birth | 1 | 2009 | 9 | 0.300 |
Why?
|
| Gene Dosage | 4 | 2016 | 75 | 0.300 |
Why?
|
| Erythromycin | 1 | 2009 | 14 | 0.300 |
Why?
|
| Azithromycin | 1 | 2009 | 7 | 0.300 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 97 | 0.300 |
Why?
|
| Vehicle Emissions | 4 | 2010 | 22 | 0.300 |
Why?
|
| Comet Assay | 4 | 2011 | 77 | 0.300 |
Why?
|
| Airway Remodeling | 4 | 2018 | 12 | 0.290 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2015 | 105 | 0.290 |
Why?
|
| STAT6 Transcription Factor | 2 | 2018 | 17 | 0.280 |
Why?
|
| Sperm-Ovum Interactions | 2 | 2022 | 14 | 0.280 |
Why?
|
| Risk Assessment | 5 | 2018 | 863 | 0.280 |
Why?
|
| Chromatin | 7 | 2013 | 186 | 0.270 |
Why?
|
| Cause of Death | 3 | 2018 | 186 | 0.270 |
Why?
|
| Sperm Head | 2 | 2009 | 10 | 0.270 |
Why?
|
| Nomograms | 2 | 2017 | 14 | 0.270 |
Why?
|
| DNA Fragmentation | 4 | 2013 | 98 | 0.260 |
Why?
|
| Deoxyribonucleases | 1 | 2007 | 27 | 0.260 |
Why?
|
| Chromosomes | 1 | 2007 | 43 | 0.260 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2007 | 8 | 0.260 |
Why?
|
| Gene Transfer Techniques | 1 | 2007 | 53 | 0.260 |
Why?
|
| Propensity Score | 4 | 2020 | 59 | 0.260 |
Why?
|
| DNA Breaks | 1 | 2006 | 6 | 0.260 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 10 | 0.260 |
Why?
|
| Bleomycin | 2 | 2024 | 20 | 0.260 |
Why?
|
| Time Factors | 6 | 2018 | 1857 | 0.250 |
Why?
|
| Airway Obstruction | 2 | 2019 | 9 | 0.250 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 95 | 0.240 |
Why?
|
| Chromatin Assembly and Disassembly | 4 | 2012 | 45 | 0.240 |
Why?
|
| Fertility | 5 | 2022 | 62 | 0.240 |
Why?
|
| Gene Knock-In Techniques | 1 | 2025 | 18 | 0.240 |
Why?
|
| Hospitalization | 5 | 2017 | 485 | 0.240 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2025 | 192 | 0.240 |
Why?
|
| Transforming Growth Factor beta | 5 | 2016 | 216 | 0.230 |
Why?
|
| Haploidy | 2 | 2016 | 16 | 0.230 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 101 | 0.230 |
Why?
|
| Disulfiram | 1 | 2024 | 2 | 0.220 |
Why?
|
| Nuclear Proteins | 3 | 2012 | 333 | 0.220 |
Why?
|
| Cytokines | 6 | 2018 | 678 | 0.220 |
Why?
|
| Folic Acid Antagonists | 1 | 2004 | 3 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2018 | 2157 | 0.220 |
Why?
|
| Methotrexate | 1 | 2004 | 22 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2019 | 213 | 0.210 |
Why?
|
| Mesenchymal Stem Cells | 2 | 2016 | 72 | 0.190 |
Why?
|
| Dyspnea | 2 | 2020 | 22 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 2 | 2019 | 33 | 0.190 |
Why?
|
| Age Factors | 5 | 2018 | 1154 | 0.190 |
Why?
|
| Behavior, Animal | 1 | 2025 | 373 | 0.190 |
Why?
|
| Prognosis | 4 | 2018 | 861 | 0.190 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2002 | 1 | 0.190 |
Why?
|
| Radiography, Thoracic | 1 | 2002 | 12 | 0.190 |
Why?
|
| Mice, Inbred DBA | 5 | 2013 | 73 | 0.190 |
Why?
|
| Histamine | 2 | 2014 | 19 | 0.190 |
Why?
|
| Postoperative Complications | 3 | 2019 | 263 | 0.180 |
Why?
|
| Immunoglobulin G | 5 | 2016 | 259 | 0.180 |
Why?
|
| Meiosis | 2 | 2014 | 67 | 0.180 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2019 | 15 | 0.180 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 116 | 0.170 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2019 | 14 | 0.170 |
Why?
|
| Fibrosis | 5 | 2016 | 169 | 0.170 |
Why?
|
| Hemoptysis | 1 | 2020 | 3 | 0.170 |
Why?
|
| Blastocyst | 2 | 2014 | 50 | 0.170 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2020 | 1 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 23 | 0.170 |
Why?
|
| Congenital Abnormalities | 1 | 2020 | 21 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 374 | 0.160 |
Why?
|
| Macrophages | 1 | 2024 | 529 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1067 | 0.160 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2010 | 15 | 0.160 |
Why?
|
| Maximal Expiratory Flow-Volume Curves | 1 | 2019 | 1 | 0.160 |
Why?
|
| Piperazines | 2 | 2019 | 120 | 0.160 |
Why?
|
| Pleural Effusion | 2 | 2017 | 8 | 0.160 |
Why?
|
| Fertilization | 4 | 2022 | 37 | 0.160 |
Why?
|
| Fetal Growth Retardation | 1 | 2020 | 53 | 0.160 |
Why?
|
| Karyotyping | 2 | 2010 | 45 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2014 | 137 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2019 | 32 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 94 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 719 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 102 | 0.150 |
Why?
|
| Cell Migration Inhibition | 2 | 2009 | 5 | 0.150 |
Why?
|
| Phosphorylation | 2 | 2018 | 986 | 0.150 |
Why?
|
| Carcinoma | 1 | 2020 | 108 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 432 | 0.150 |
Why?
|
| Embryo, Mammalian | 3 | 2009 | 157 | 0.150 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 11 | 0.150 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2018 | 7 | 0.150 |
Why?
|
| Aneurysm, Infected | 1 | 2018 | 1 | 0.150 |
Why?
|
| Citrobacter koseri | 1 | 2018 | 1 | 0.150 |
Why?
|
| Naphthalenes | 1 | 2019 | 38 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2019 | 300 | 0.150 |
Why?
|
| Aspergillus | 1 | 2018 | 14 | 0.150 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 12 | 0.150 |
Why?
|
| Peptide Hydrolases | 1 | 2018 | 44 | 0.150 |
Why?
|
| Interleukins | 1 | 2018 | 40 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2018 | 17 | 0.140 |
Why?
|
| Sex Factors | 3 | 2017 | 1028 | 0.140 |
Why?
|
| Chemotaxis | 2 | 2009 | 68 | 0.140 |
Why?
|
| Mice, Knockout | 5 | 2025 | 1035 | 0.140 |
Why?
|
| Cell Movement | 4 | 2024 | 655 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2010 | 575 | 0.140 |
Why?
|
| Mycobacterium Infections | 1 | 2018 | 16 | 0.140 |
Why?
|
| Thoracic Arteries | 1 | 2017 | 1 | 0.140 |
Why?
|
| Popliteal Artery | 1 | 2017 | 2 | 0.140 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2010 | 92 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 22 | 0.140 |
Why?
|
| Administration, Inhalation | 2 | 2016 | 92 | 0.140 |
Why?
|
| Oncogene Protein v-akt | 1 | 2018 | 20 | 0.140 |
Why?
|
| Pneumonectomy | 1 | 2017 | 10 | 0.140 |
Why?
|
| Pleurodesis | 1 | 2017 | 1 | 0.140 |
Why?
|
| Talc | 1 | 2017 | 3 | 0.140 |
Why?
|
| T-Box Domain Proteins | 1 | 2017 | 7 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2017 | 5 | 0.140 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2018 | 102 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2018 | 260 | 0.130 |
Why?
|
| Survival Rate | 1 | 2018 | 355 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2018 | 171 | 0.130 |
Why?
|
| Nuclear Matrix | 2 | 2007 | 17 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 234 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 159 | 0.130 |
Why?
|
| Interleukin-6 | 2 | 2016 | 165 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 218 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2018 | 108 | 0.130 |
Why?
|
| Culture Media | 2 | 2011 | 96 | 0.130 |
Why?
|
| Gene Expression Regulation | 4 | 2017 | 1070 | 0.130 |
Why?
|
| Anesthetics, General | 1 | 2017 | 1 | 0.130 |
Why?
|
| Seminiferous Epithelium | 1 | 2017 | 5 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 49 | 0.130 |
Why?
|
| Thrombosis | 1 | 2017 | 81 | 0.130 |
Why?
|
| Uterus | 2 | 2007 | 52 | 0.130 |
Why?
|
| Chickenpox | 1 | 2016 | 6 | 0.130 |
Why?
|
| Herpesvirus 3, Human | 1 | 2016 | 13 | 0.130 |
Why?
|
| Fracture Fixation | 1 | 2016 | 1 | 0.130 |
Why?
|
| Exosomes | 1 | 2018 | 126 | 0.130 |
Why?
|
| Neutrophils | 2 | 2015 | 145 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 24 | 0.120 |
Why?
|
| Meigs Syndrome | 1 | 2016 | 1 | 0.120 |
Why?
|
| Health Status | 2 | 2018 | 442 | 0.120 |
Why?
|
| Pericardial Effusion | 1 | 2016 | 6 | 0.120 |
Why?
|
| Glucose | 2 | 2011 | 244 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 54 | 0.120 |
Why?
|
| Respiratory Function Tests | 2 | 2016 | 61 | 0.120 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sperm Count | 3 | 2011 | 28 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2017 | 245 | 0.120 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 18 | 0.120 |
Why?
|
| Sperm Motility | 3 | 2011 | 47 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 2 | 2014 | 196 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1455 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2018 | 302 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2016 | 44 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 223 | 0.110 |
Why?
|
| Spermatogonia | 1 | 2016 | 57 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 497 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2018 | 536 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 291 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2014 | 140 | 0.110 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2014 | 5 | 0.110 |
Why?
|
| Zinc Fingers | 2 | 2025 | 28 | 0.110 |
Why?
|
| Robotics | 1 | 2015 | 43 | 0.110 |
Why?
|
| Respiratory System | 2 | 2012 | 31 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 539 | 0.110 |
Why?
|
| Interphase | 1 | 2014 | 6 | 0.110 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 704 | 0.110 |
Why?
|
| Receptors, Histamine H1 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 29 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2014 | 23 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2016 | 306 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 179 | 0.110 |
Why?
|
| Ligands | 1 | 2015 | 388 | 0.110 |
Why?
|
| Allergens | 2 | 2018 | 65 | 0.110 |
Why?
|
| Oxidative Stress | 3 | 2009 | 1003 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 18 | 0.100 |
Why?
|
| Niacinamide | 1 | 2014 | 16 | 0.100 |
Why?
|
| Estrone | 2 | 2010 | 21 | 0.100 |
Why?
|
| Stromal Cells | 1 | 2014 | 55 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2025 | 1596 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 532 | 0.100 |
Why?
|
| Embryo Transfer | 3 | 2020 | 33 | 0.100 |
Why?
|
| Cell Count | 3 | 2010 | 145 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2014 | 63 | 0.100 |
Why?
|
| Reproduction | 1 | 2013 | 94 | 0.100 |
Why?
|
| Cricetinae | 2 | 2004 | 241 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2018 | 518 | 0.090 |
Why?
|
| Cell Line | 3 | 2019 | 1410 | 0.090 |
Why?
|
| Young Adult | 3 | 2018 | 5080 | 0.090 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2010 | 12 | 0.090 |
Why?
|
| Pulmonary Emphysema | 1 | 2012 | 13 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2014 | 883 | 0.090 |
Why?
|
| NF-kappa B | 1 | 2014 | 358 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 518 | 0.090 |
Why?
|
| Estradiol | 2 | 2010 | 268 | 0.090 |
Why?
|
| Lung Volume Measurements | 1 | 2011 | 3 | 0.090 |
Why?
|
| Placenta | 2 | 2010 | 117 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 18 | 0.080 |
Why?
|
| Serum Albumin, Bovine | 1 | 2011 | 49 | 0.080 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 23 | 0.080 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2010 | 2 | 0.080 |
Why?
|
| Bronchial Neoplasms | 1 | 2010 | 2 | 0.080 |
Why?
|
| Mice, Inbred Strains | 2 | 2009 | 114 | 0.080 |
Why?
|
| Disease Progression | 3 | 2018 | 667 | 0.080 |
Why?
|
| Papilloma | 1 | 2010 | 17 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 14 | 0.080 |
Why?
|
| Pulmonary Eosinophilia | 2 | 2018 | 5 | 0.080 |
Why?
|
| Freezing | 1 | 2010 | 17 | 0.080 |
Why?
|
| Protamines | 1 | 2010 | 21 | 0.080 |
Why?
|
| Eosinophils | 2 | 2009 | 24 | 0.080 |
Why?
|
| Fetus | 1 | 2010 | 101 | 0.080 |
Why?
|
| Progesterone | 1 | 2010 | 121 | 0.080 |
Why?
|
| Procaterol | 1 | 2009 | 1 | 0.080 |
Why?
|
| Sperm Capacitation | 1 | 2009 | 4 | 0.080 |
Why?
|
| Parthenogenesis | 1 | 2009 | 9 | 0.080 |
Why?
|
| Germ Cells | 1 | 2009 | 74 | 0.080 |
Why?
|
| Likelihood Functions | 1 | 2009 | 62 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2010 | 55 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1019 | 0.070 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2008 | 1 | 0.070 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2008 | 2 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 186 | 0.070 |
Why?
|
| Steroids | 1 | 2009 | 45 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 79 | 0.070 |
Why?
|
| Immunoglobulin E | 4 | 2010 | 61 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2007 | 269 | 0.070 |
Why?
|
| Organ Size | 1 | 2009 | 170 | 0.070 |
Why?
|
| Phenotype | 3 | 2020 | 780 | 0.070 |
Why?
|
| Particulate Matter | 1 | 2009 | 83 | 0.070 |
Why?
|
| Spirometry | 2 | 2019 | 40 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 934 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 91 | 0.070 |
Why?
|
| Acetylcysteine | 2 | 2009 | 57 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 317 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 74 | 0.070 |
Why?
|
| Cell Membrane | 1 | 2010 | 403 | 0.070 |
Why?
|
| ROC Curve | 2 | 2019 | 159 | 0.070 |
Why?
|
| Plant Proteins | 1 | 2008 | 102 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 167 | 0.070 |
Why?
|
| Cryoprotective Agents | 1 | 2007 | 6 | 0.070 |
Why?
|
| Seminal Vesicles | 1 | 2007 | 9 | 0.070 |
Why?
|
| Albuterol | 1 | 2007 | 7 | 0.070 |
Why?
|
| Bronchitis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Aphidicolin | 1 | 2007 | 3 | 0.070 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2007 | 6 | 0.070 |
Why?
|
| Androstadienes | 1 | 2007 | 19 | 0.070 |
Why?
|
| Vas Deferens | 1 | 2007 | 7 | 0.070 |
Why?
|
| Freeze Drying | 1 | 2007 | 29 | 0.070 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2007 | 29 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 518 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2007 | 48 | 0.070 |
Why?
|
| Chlortetracycline | 1 | 2007 | 3 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 440 | 0.070 |
Why?
|
| Adolescent | 5 | 2019 | 6081 | 0.060 |
Why?
|
| Leukocyte Count | 3 | 2016 | 69 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2009 | 239 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2006 | 20 | 0.060 |
Why?
|
| Sexual Behavior, Animal | 1 | 2007 | 64 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2007 | 107 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1285 | 0.060 |
Why?
|
| Pneumothorax | 2 | 2017 | 9 | 0.060 |
Why?
|
| Plasmids | 1 | 2007 | 244 | 0.060 |
Why?
|
| Consciousness Disorders | 2 | 2017 | 2 | 0.060 |
Why?
|
| Genome | 1 | 2007 | 149 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 2676 | 0.060 |
Why?
|
| Apoptosis | 3 | 2025 | 1568 | 0.060 |
Why?
|
| Mesocricetus | 2 | 2004 | 56 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2022 | 1271 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 189 | 0.050 |
Why?
|
| Fibronectins | 3 | 2009 | 69 | 0.050 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2004 | 20 | 0.050 |
Why?
|
| Cycloheximide | 1 | 2004 | 30 | 0.050 |
Why?
|
| Threonine | 1 | 2004 | 24 | 0.050 |
Why?
|
| Interleukin-1 | 1 | 2004 | 39 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2004 | 24 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2004 | 64 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 120 | 0.050 |
Why?
|
| Oxyquinoline | 1 | 2003 | 6 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 139 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2016 | 238 | 0.050 |
Why?
|
| Vital Capacity | 2 | 2017 | 44 | 0.050 |
Why?
|
| Acrosome | 1 | 2002 | 2 | 0.050 |
Why?
|
| Forced Expiratory Volume | 2 | 2017 | 75 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 32 | 0.050 |
Why?
|
| Microinjections | 1 | 2002 | 50 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2002 | 61 | 0.050 |
Why?
|
| Zinc | 1 | 2003 | 131 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 13 | 0.050 |
Why?
|
| Monocytes | 1 | 2024 | 277 | 0.050 |
Why?
|
| Salicylates | 1 | 2002 | 9 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2002 | 17 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2002 | 30 | 0.050 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2021 | 3 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2025 | 403 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 1124 | 0.040 |
Why?
|
| Light | 1 | 2002 | 185 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 91 | 0.040 |
Why?
|
| Papain | 1 | 2020 | 5 | 0.040 |
Why?
|
| Collagen | 2 | 2014 | 181 | 0.040 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 67 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 67 | 0.040 |
Why?
|
| Rehabilitation Centers | 1 | 2020 | 10 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 72 | 0.040 |
Why?
|
| Sex Chromosomes | 2 | 2010 | 16 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 9 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2020 | 57 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cell Migration Assays | 2 | 2009 | 3 | 0.040 |
Why?
|
| Proteins | 1 | 2022 | 382 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2019 | 74 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 211 | 0.040 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2019 | 4 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 436 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 22 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2019 | 29 | 0.040 |
Why?
|
| Zingiberaceae | 1 | 2018 | 1 | 0.040 |
Why?
|
| Tokyo | 1 | 2018 | 5 | 0.040 |
Why?
|
| Chromosomes, Human, Y | 1 | 2019 | 15 | 0.040 |
Why?
|
| Zanthoxylum | 1 | 2018 | 4 | 0.040 |
Why?
|
| Panax | 1 | 2018 | 6 | 0.040 |
Why?
|
| Brachiocephalic Trunk | 1 | 2018 | 1 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2018 | 10 | 0.040 |
Why?
|
| Lung Diseases, Fungal | 1 | 2018 | 21 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 53 | 0.040 |
Why?
|
| RNA | 1 | 2020 | 266 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 74 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 259 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 19 | 0.040 |
Why?
|
| Carboplatin | 1 | 2018 | 20 | 0.040 |
Why?
|
| Picibanil | 1 | 2017 | 2 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 287 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 155 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2017 | 49 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 81 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2019 | 346 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2017 | 74 | 0.030 |
Why?
|
| Tidal Volume | 1 | 2017 | 9 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 9 | 0.030 |
Why?
|
| Biopsy | 2 | 2008 | 177 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1078 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 203 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2017 | 22 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 1759 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 122 | 0.030 |
Why?
|
| Breath Tests | 1 | 2016 | 24 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 694 | 0.030 |
Why?
|
| Allopurinol | 1 | 2016 | 13 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2016 | 26 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 272 | 0.030 |
Why?
|
| Cell Survival | 2 | 2011 | 945 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 3156 | 0.030 |
Why?
|
| Polyethylene Terephthalates | 1 | 2015 | 2 | 0.030 |
Why?
|
| Electromagnetic Phenomena | 1 | 2015 | 3 | 0.030 |
Why?
|
| Miniaturization | 1 | 2015 | 5 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 31 | 0.030 |
Why?
|
| Antioxidants | 2 | 2009 | 443 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 2008 | 352 | 0.030 |
Why?
|
| Lasers | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cordotomy | 1 | 1994 | 1 | 0.030 |
Why?
|
| Pleura | 1 | 1994 | 5 | 0.030 |
Why?
|
| Thorax | 1 | 1994 | 6 | 0.030 |
Why?
|
| Nerve Block | 1 | 1994 | 5 | 0.030 |
Why?
|
| Emergencies | 1 | 2014 | 32 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 145 | 0.030 |
Why?
|
| Glucuronidase | 1 | 2014 | 21 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 592 | 0.030 |
Why?
|
| Spermatocytes | 1 | 2014 | 27 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 25 | 0.030 |
Why?
|
| Dipeptides | 1 | 2014 | 31 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2014 | 51 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 196 | 0.030 |
Why?
|
| Patents as Topic | 1 | 2014 | 14 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 701 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 173 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 302 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2013 | 138 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 968 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 65 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 93 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 587 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 1600 | 0.020 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2011 | 5 | 0.020 |
Why?
|
| Respiratory Muscles | 1 | 2011 | 10 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2011 | 13 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 2011 | 14 | 0.020 |
Why?
|
| Histones | 1 | 2013 | 197 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 491 | 0.020 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2010 | 7 | 0.020 |
Why?
|
| Versicans | 1 | 2010 | 8 | 0.020 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2010 | 10 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 35 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 95 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2010 | 8 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 983 | 0.020 |
Why?
|
| Vimentin | 1 | 2010 | 44 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2010 | 47 | 0.020 |
Why?
|
| Ovary | 1 | 2010 | 113 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 102 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 93 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 80 | 0.020 |
Why?
|
| Ranitidine | 1 | 2009 | 4 | 0.020 |
Why?
|
| Receptors, Histamine | 1 | 2009 | 3 | 0.020 |
Why?
|
| Diphenhydramine | 1 | 2009 | 5 | 0.020 |
Why?
|
| Histamine Antagonists | 1 | 2009 | 6 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1612 | 0.020 |
Why?
|
| Chemokines | 1 | 2010 | 96 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 1542 | 0.020 |
Why?
|
| Glutathione | 1 | 2010 | 171 | 0.020 |
Why?
|
| Goblet Cells | 1 | 2009 | 12 | 0.020 |
Why?
|
| Estriol | 1 | 2009 | 9 | 0.020 |
Why?
|
| Sodium Azide | 1 | 2009 | 2 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 127 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 232 | 0.020 |
Why?
|
| Ambrosia | 1 | 2008 | 2 | 0.020 |
Why?
|
| Antigens, Plant | 1 | 2008 | 3 | 0.020 |
Why?
|
| Desensitization, Immunologic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Pollen | 1 | 2008 | 5 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 18 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 195 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2011 | 241 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2008 | 35 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 88 | 0.020 |
Why?
|
| Models, Animal | 1 | 2009 | 151 | 0.020 |
Why?
|
| Birth Weight | 1 | 2009 | 95 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2008 | 52 | 0.020 |
Why?
|
| Gels | 1 | 2008 | 45 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2008 | 44 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2008 | 87 | 0.020 |
Why?
|
| Imidazoles | 1 | 2009 | 142 | 0.020 |
Why?
|
| Pyridines | 1 | 2009 | 139 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 187 | 0.020 |
Why?
|
| Deoxyribonuclease I | 1 | 2007 | 26 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 249 | 0.020 |
Why?
|
| Glutathione Transferase | 1 | 2008 | 90 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2007 | 47 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 511 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2007 | 17 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2008 | 144 | 0.020 |
Why?
|
| Species Specificity | 1 | 2008 | 286 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 458 | 0.020 |
Why?
|
| Sputum | 1 | 2006 | 22 | 0.020 |
Why?
|
| Th2 Cells | 1 | 2006 | 62 | 0.020 |
Why?
|
| Acrosome Reaction | 1 | 2006 | 3 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2006 | 75 | 0.020 |
Why?
|
| Calcimycin | 1 | 2006 | 11 | 0.020 |
Why?
|
| Ionophores | 1 | 2006 | 11 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 317 | 0.020 |
Why?
|
| Detergents | 1 | 2006 | 25 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 97 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2006 | 55 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2006 | 139 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 98 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 184 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2006 | 456 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 712 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2006 | 386 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 2003 | 61 | 0.010 |
Why?
|
| Gestational Age | 1 | 2004 | 200 | 0.010 |
Why?
|
| Neoplasms | 1 | 1994 | 1377 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2003 | 184 | 0.010 |
Why?
|
| Common Cold | 1 | 2002 | 5 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2003 | 570 | 0.010 |
Why?
|
| Phenol | 1 | 1994 | 5 | 0.010 |
Why?
|
| Subarachnoid Space | 1 | 1994 | 3 | 0.010 |
Why?
|
| Injections | 1 | 1994 | 42 | 0.010 |
Why?
|
| Syndrome | 1 | 1994 | 73 | 0.010 |
Why?
|
| Phenols | 1 | 1994 | 107 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 290 | 0.010 |
Why?
|